Acadian Asset Management’s Pacific Biosciences PACB Stock Holding History

Acadian Asset Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Buy	793,332 +374,541	+89%	+$545K	﹤0.01%	1181
2026 Q1	$549K	Sell	418,791 -22,459	-5%	-$40.2K	﹤0.01%	1335
2025 Q4	$822K	Buy	441,250 +418,134	+1,809%	+$803K	﹤0.01%	1169
2025 Q3	$29K	Buy	+23,116	New	+$31.3K	﹤0.01%	1728
2020 Q3	–	Sell	-128,624	Closed	-$444K	–	2311
2020 Q2	$444K	Buy	+128,624	New	+$438K	﹤0.01%	1235
2017 Q2	–	Sell	-71,084	Closed	-$368K	–	1545
2017 Q1	$368K	Buy	+71,084	New	+$348K	﹤0.01%	949

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management's PACB Position: Q2 2026 in Review

Acadian Asset Management increased its Pacific Biosciences (PACB) stake by 89% in Q2 2026, buying an estimated $545K and bringing the position to 793,332 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1181.

Acadian Asset Management first reported a position in PACB in Q1 2017 and has held it in 6 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Acadian Asset Management held 793,332 shares of Pacific Biosciences worth $1.33M as of Q2 2026.
Acadian Asset Management bought 374,541 Pacific Biosciences shares in Q2 2026, an estimated $545K.
Pacific Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1181 holding.
Acadian Asset Management first reported a position in Pacific Biosciences in Q1 2017 and has held it in 6 quarters since.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.